JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012].
Jpn J Antibiot
PUBLISHED: 06-25-2014
Show Abstract
Hide Abstract
The nationwide surveillance of antibacterial susceptibility to meropenem (MEPM) and other parenteral antibiotics against clinical isolates during 2012 in Japan was conducted. A total of 2985 strains including 955 strains of Gram-positive bacteria, 1782 strains of Gram-negative bacteria, and 248 strains of anaerobic bacteria obtained from 31 medical institutions were examined. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). 2. Of all species tested, there were no species, which MIC90 of MEPM was more than 4-fold higher than those in our previous studies in 2009 or 2006. Therefore, the tendency to increase in antimicrobial resistance rates was not observed. 3. MEPM resistance against Pseudomonas aeruginosa was 17.8% (56/315 strains). Compared to our previous results, it was the lowest than that in 2006 and 2009. 4. Carbapenem-resistant Klebsiella pneumoniae, and multi-drug-resistant Acinetobacter species, which emerged in worldwide, were not observed. 5. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 6.2% (59/951 strains) in enterobacteriaceae, which increased compared with that of our previous studies in 2009 or before. Whereas, the proportion of metallo-beta-lactamase strains was 1.6% (5/315 strains) in P. aeruginosa, which was stable. In conclusion, the results from this surveillance suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 17 years passed after available for commercial use in Japan.
Related JoVE Video
[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].
Jpn J Antibiot
PUBLISHED: 07-05-2011
Show Abstract
Hide Abstract
The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; (1) MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multidrug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). (2) MEPM maintained potent and stable antibacterial activity against Pseudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. (3) The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-beta-lactamase strains was 2.0% (6 strains) in P. aeruginosa. (4) Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.
Related JoVE Video
[In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007].
Keizo Yamaguchi, Akira Ohno, Yoshikazu Ishii, Kazuhiro Tateda, Morihiro Iwata, Makoto Kanda, Kouji Akizawa, Chikara Shimizu, Shinichirou Kon, Kastushi Nakamura, Keiko Matsuda, Makoto Tominaga, Takuo Nakagawa, Akihiro Sugita, Tatsumi Ito, Jun Kato, Akira Suwabe, Kumiko Yamahata, Chizuko Kawamura, Hiromi Tashiro, Hiroko Horiuchi, Yosei Katayama, Shigemi Kondou, Shigeki Misawa, Misturu Murata, Yoshio Kobayashi, Hideyuki Okamoto, Kenichiro Yamazaki, Motoi Okada, Kosuke Haruki, Harushige Kanno, Masanori Aihara, Shigefumi Maesaki, Giichi Hashikita, Eiji Miyajima, Midori Sumitomo, Takefumi Saito, Nobuo Yamane, Chieko Kawashima, Takahisa Akiyama, Tamio Ieiri, Yoshitaka Yamamoto, Yuki Okamoto, Hidetoshi Okabe, Kunihiko Moro, Masayo Shigeta, Haruyoshi Yoshida, Masanobu Yamashita, Yukio Hida, Takayuki Takubo, Tadashi Kusakabe, Hiroya Masaki, Hitoshi Heijyou, Hideo Nakaya, Kunimitsu Kawahara, Reiko Sano, Syuji Matsuo, Hisashi Kono, Yosuke Yuzuki, Norio Ikeda, Masayo Idomuki, Masayuki Soma, Go Yamamoto, Syohiro Kinoshita, Seiji Kawano, Mikio Oka, Nobuchika Kusano, Dongchon Kang, Junko Ono, Minoru Yasujima, Makoto Miki, Masato Hayashi, Syunji Okubo, Syunkou Toyoshima, Mitsuo Kaku, Imao Sekine, Joji Shiotani, Hajime Horiuchi, Yoko Tazawa, Akiko Yoneyama, Kazunari Kumasaka, Kazuhiko Koike, Nobuyuki Taniguchi, Yukio Ozaki, Takashi Uchida, Masami Murakami, Kazuhisa Inuzuka, Hideo Gonda, Ikuo Yamaguchi, Yoshinori Fujimoto, Junji Iriyama, Yuko Asano, Hitoshi Genma, Masato Maekawa, Hitoshi Yoshimura, Kaname Nakatani, Hisashi Baba, Satoshi Ichiyama, Shinichi Fujita, Masao Kuwabara, Toshiro Okazaki, Hiromitsu Fujiwara, Hiromi Ota, Astushi Nagai, Jun Fujita, Kiyoshi Negayama, Tetsuro Sugiura, Mikio Kamioka, Mitsuharu Murase, Nobuhisa Yamane, Isamu Nakasone, Akihiko Okayama, Yosuke Aoki, Koji Kusaba, Yukari Nakashima, Hiroaki Miyanohara, Kazufumi Hiramatsu, Tetsunori Saikawa, Katsunori Yanagihara, Junichi Matsuda, Shigeru Kohno, Koichi Mashiba.
Jpn J Antibiot
PUBLISHED: 10-29-2009
Show Abstract
Hide Abstract
We have reported in this journal in vitro susceptibilities of clinical isolates to antibiotics every year since 1992. In this paper, we report the results of an analysis of in vitro susceptibilities of 12,919 clinical isolates from 72 centers in Japan to selected antibiotics in 2007 compared with the results from previous years. The common respiratory pathogens, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae maintained a high susceptibility to fluoroquinolones (FQs). The resistance of S. pyogenes to macrolides has been increasing every year and this was especially clear this year. Most strains of Enterobacteriaceae except for Escherichia coli showed a high susceptibility to FQs. Almost 30% of E. coli strains were resistant to FQs and the resistance increased further this year. FQs resistance of methicillin-resistant Staphylococcus aureus (MRSA) was approximately 95% with the exception of 45% for sitafloxacin (STFX). FQs resistance of methicillin-susceptible S. aureus (MSSA) was low at about 10%. FQs resistance of methicillin-resistant coagulase negative Staphylococci (MRCNS) was higher than that of methicillin-susceptible coagulase negative Staphylococci (MSCNS), but it was lower than that of MRSA. However, FQs resistance of MSCNS was higher than that of MSSA. FQs resistance of Enterococcus faecalis was 22.5% to 29.6%, while that of Enterococcusfaecium was more than 85% except for STFX (58.3%). In clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections, FQs resistance was 21-27%, which was higher than that of P. aeruginosa from respiratory tract infections at 13-21%, which was the same trend as in past years. Multidrug resistant strains accounted for 5.6% in the urinary tract and 1.8% in the respiratory tract. Acinetobacter spp. showed high susceptibility to FQs. The carbapenem resistant strains, which present a problem at present, accounted for 2.7%. Neisseria gonorrhoeae showed high resistance of 86-88% to FQs. The results of the present survey indicated that although methicillin-resistant Staphylococci, Enterococci, E. coli, P. aeruginosa, and N. gonorrhoeae showed resistance tendencies, and other species maintained high susceptibility rates more than 90% against FQs, which have been used clinically for over 15 years.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.